<code id='85A6F4DBF1'></code><style id='85A6F4DBF1'></style>
    • <acronym id='85A6F4DBF1'></acronym>
      <center id='85A6F4DBF1'><center id='85A6F4DBF1'><tfoot id='85A6F4DBF1'></tfoot></center><abbr id='85A6F4DBF1'><dir id='85A6F4DBF1'><tfoot id='85A6F4DBF1'></tfoot><noframes id='85A6F4DBF1'>

    • <optgroup id='85A6F4DBF1'><strike id='85A6F4DBF1'><sup id='85A6F4DBF1'></sup></strike><code id='85A6F4DBF1'></code></optgroup>
        1. <b id='85A6F4DBF1'><label id='85A6F4DBF1'><select id='85A6F4DBF1'><dt id='85A6F4DBF1'><span id='85A6F4DBF1'></span></dt></select></label></b><u id='85A6F4DBF1'></u>
          <i id='85A6F4DBF1'><strike id='85A6F4DBF1'><tt id='85A6F4DBF1'><pre id='85A6F4DBF1'></pre></tt></strike></i>

          
          WSS
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          entertainment